Table 4. Analysis of response and survival of patients with gastric cancer accepted capecitabine therapy: correlation with TP and TS mRNA expression (univariate analysis).
| Biomarker | RR% | P | PFS (month) | P | OS (month) | P |
|---|---|---|---|---|---|---|
| TS≤5.7 | 16/29 (55.2%) | 5.9 | 9.7 | |||
| TS>5.7 | 8/28 (28.6%) | 0.042 | 3.2 | 0.617 | 7.3 | 0.257 |
| TP≤1.24 | 8/28 (27.6%) | 3.5 | 6.6 | |||
| TP>1.24 | 16/28 (57.1%) | 0.024 | 5.9 | 0.469 | 11.6 | 0.204 |
| TS≤5.7 | 11/19 (57.9%) | 5.9 | 13.8 | |||
| TP>1.24 | ||||||
| TS≤5.7 | 5/10 (50%) | 0.714 | 3.9 | 0.290 | 9.7 | 0.245 |
| TP≤1.24 | ||||||
| TS>5.7 | 3/19 (15.8%) | 0.007 | 3.0 | 0.498 | 6.6 | 0.054 |
| TP≤1.24 | ||||||
| TS>5.7 | 5/9 (55.6%) | 1.0 | 4.0 | 0.482 | 9.4 | 0.535 |
| TP>1.24 |